LINEAGE CELL THERAPEUTICS IN (LCTX) Stock News

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Examining the Future: Lineage Cell Therapeutics's Earnings Outlook

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 15.69% and 385.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: EDIT

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024

LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

Lineage to Present at 2024 BIO International Convention

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium